Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors

AIDS Research and Human Retroviruses

Volumn 16, Issue 6, 2000, Pages 517-528

  Balzarini, Jan ^a   De Clercq, Erik ^a   Carbonez, An ^b   Burt, Vikki ^c   Kleim, Jörg Peter ^c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 ETHYL 6 FLUORO 4 ISOPROPOXYCARBONYL 3,4 DIHYDRO QUINOXALIN 2(1H) ONE; ABACAVIR; CARBOVIR; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; LAMIVUDINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

ANILIDES; ANTI-HIV AGENTS; CELL LINE; DELAVIRDINE; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG RESISTANCE, MICROBIAL; FURANS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MUTATION; NEVIRAPINE; OXAZINES; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS; URACIL;

EID: 0034630305     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308936     Document Type: Article

References (19)

1. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Nusinoff Lehrman S, Gallo RC, Bolognesi, D, Barry DW, and Broder S: 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl Acad Sci USA 1985;82:7096-7100.
2. Mitsuya H and Broder S: Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc Natal Acad Sci USA 1986;83:1911-1915.
3. Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, and Vandeputte M: Both 2′,3′-dideoxythymidine and its 2′,3′-unsaturated derivative (2′,3′-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem Biophys Res Commun 1987;142:128-134.
4. Soudeyns H, Yao X-I, Gao Q, Belleau B, Kraus J-L, Nguyen-Ba N, Spira B, and Wainberg MA: Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother 1991;35:1386-1390.
5. Daluge SM, Good SS, Martin MT, Tibbels SR, Miller WH, Averett DR, St Clair MH, and Ayers KM: 1592U89 succinate - a novel carbocyclic nucleoside analogue with potent, selective anti-HIV activity. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC, 1994, p. 7. [Abstract 16]
6. Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holý A, and De Clercq E: Phosphonylmethoxyethyl purine derivatives: A new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988;32:1025-1030.
7. Balzarini J, Holý A, Jindrich L, Naesens L, Snoeck R, Schols D, and De Clerq E: Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6- diamino-purine. Antimicrob Agents Chemother 1993;37:332-338.
8. Balzarini J, Hao Z, Herdewijn P, Johns DG, and De Clercq E: Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 1991;88:1499-1503.
9. Balzarini J and De Clercq E: Analysis of inhibition of retroviral reverse transcriptase. Methods Enzymol 1996;275:472-502.
10. De Clerq E: Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491-2517.
11. Connolly KJ and Hammer SM: Antiretroviral therapy: Reverse transcriptase inhibition. Antimicrob Agents Chemother 1992;36: 245-254.
12. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JRA, Olsen DB, Carroll SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen IW, Schleif WA, Sardana VV, Long WJ, Byrenes VW, and Emini EA: L-743,726 (DMP-266): A novel, highly-potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1995;39:2602-2609.
13. Seki M, Sadakata Y, Yuasa S, and Baba M: Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem Chemother 1995;6:73-79.
14. th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 1999, no. 600.
15. Balzarini J, Pelemans H, Aquaro S, Perno C-F, Witvrouw M, Schols D, De Clercq E, and Karlsson A: Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol Pharmacol 1996;50:394-401.
16. Balzarini J, Pérez-Pérez M-J, San-Félix A, Camarasa M-J, Bathurst IC, Barr PJ, and De Clercq E: Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyl- dimethylsilyl)-β-D-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO-T). J Biol Chem 1992; 267:11831-11838.
17. Balzarini J, Pelemans H, Pérez-Pérez M-J, San-Félix A, Camarasa M-J, De Clercq E, and Karlsson A: Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol Pharmacol 1996;49:882-890.
18. Balzarini J, Pelemans H, Karlsson A, De Clercq E, and Kleim J-P: Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1996;93:13152-13157.
19. Buckheit JRW, Fliakas-Boltz V, Decker WD, Roberson JL, Strup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR, and Bader JP: Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res 1995;26:117-132.